|
Dr. Penny is the founder and Chief Executive Officer of Caris MPI, the first company to commercially introduce gene expression into oncology in the U.S. He is one of the co-founders of the International Genomics Consortium (IGC), the Chief Medical and Operating Officer of IGC, and the Executive Director of their national expression project for oncology (expO). Dr. Penny is the Principle Investigator for The Cancer Genome Atlas Project and Chairs the NIH Biospecimen, Biomolecule and Production Working Group. Dr. Penny is a recognized expert in the translation of diagnostics into patient care as well as in biorepositories. He has established two national esoteric reference medical laboratories, a national tissue bank and analysis center, and a national genomics program. He has helped bring cellular and molecular diagnostic, prognostic and therapeutic testing to patients throughout the nation with leukemia, lymphoma and solid tumors. He has headed up genomic strategies for AmeriPath, the largest provider of anatomic pathology in the United States. Dr. Penny received his B.S., M.S., Ph.D. (Genetics) and M.D. from the University of Arizona and then went on to receive his pathology training at Harvard's Brigham & Women's Hospital in Boston, Massachusetts, where he served as chief resident and completed fellowships in hematopathology and surgical pathology. Dr. Penny's contributions include a textbook in oncology, publication of articles, and directorship roles in laboratory management | 